Introduction {#S1}
============

Inflammation is initiated as the body's immune cells activate inflammatory cascades to prevent tissue damage from injury or infiltrating antigens. When successful, the inflammatory response eradicates pathogens, instigates the processes of wound healing and angiogenesis, and then subsides. Contrary to this protective homeostatic action, inflammation has been observed in a multitude of diseases, and its impact on neurological disorders has been proposed as a leading cause of disease progression in recent years. Within the CNS, microglia, known as 'the brain's immune cells,' interact with astrocytes and neurons by assuming phagocytic phenotypes and releasing inflammatory cytokines. This can cause neurodegeneration, phagocytosis of synapses, diminished neural function, microglial activation, inflammatory cytokine release, and further microglial activation until threat to the neural environment abates. Activation of astrocytes, termed astrogliosis, also occurs as part of the inflammatory process. When acute, this neuroinflammatory response is necessary and even beneficial to the neural environment in eliminating pathogens or aiding brain repair. However, when extreme threats to the neural environment such as protein aggregates (i.e., lewy bodies, neurofibrillary tangles) accumulate in the brain and protractedly sustain inflammation, continuous gliosis and apoptosis can occur as a result of unregulated inflammatory cytokine release. Continuity of this activated state results in chronic inflammation, which is implicated in virtually all neurological disorders, including AD, PD, and ALS.

The majority of neurodegenerative diseases affect the aging population, which is growing at an exponential rate due to medical advancements that have prolonged lifespan ([@B109]). For example, AD is projected to affect an estimated 13.8 million people over the age of 65 in the U.S. alone during the next few decades ([@B4]), while the number of PD patients is expected to rise to 1.24 million people in the next decade ([@B158]). Despite considerable effort and resources, drug developments to combat these neurodegenerative disorders have resulted in a mere handful of drugs that mitigate symptoms rather than slow disease progression ([@B164]). There are numerous reasons why clinical trials have thus far largely failed, including the recruitment of patients too far into disease progression. However, the greatest reason for failure may be the selection of the disease target, exemplified by the predominant focus on inhibiting amyloid or tau aggregation for reversing AD and reducing α-synuclein to treat PD. There is a great need to expand target mechanisms to encompass prevention of chronic neuroinflammation, which has been elucidated as a key factor driving neurological disease progression through multiple cascades that include processes impacting the classical targets of amyloid, tau and α-synuclein.

Mechanism and Signaling Events of Neuroinflammation in CNS Neurodegenerative Diseases {#S2}
=====================================================================================

In response to deleterious stimuli such as injury or dysregulation in the CNS, proinflammatory cytokines and in particular, TNF-α, are released by brain endothelial cells, neurons, infiltrating immune cells, and resident glial cells ([@B228]; [@B88]; [@B208]; [@B206]). This leads to activation of transcription factors by MAPKs, namely ERK, JNK, and p38, causing the upregulation of oxidative stress inducers and TNF-α, and the activation of microglia, astrocytes, and the NF-κB pathway ([@B270]). The NF-κB pathway can be canonically or non-canonically activated. Canonical activation involves direct NF-κB activation by TNF-α or proinflammatory triggers, such as ROS, and leads to increased proinflammatory gene expression. Canonical activation is necessary for a fast and acute response to both peripheral and central threats and injuries. In contrast, non-canonical activation occurs in response to various stimuli such as lymphotoxin and is slower, with specific, long-term effects. Lymphotoxin is a proinflammatory cytokine that activates the NF-κB pathway, initiating changes in gene expression crucial for not only inflammation, but also for processes such as lymph node development and gastrointestinal immune homeostasis ([@B21]). Although most NF-κB activation is canonical, non-canonical activation has been implicated in neural stem cell pluripotency and possibly differentiation ([@B286]; [@B293]; [@B283]).

Whereas an inflammatory response is fundamental to successfully fight off disease and reestablish homeostasis in response to injury, an acute inflammation can become chronic and exacerbate disease when inflammatory pathways are mis-regulated. Neuronal NF-κB activation generally promotes cell survival and can mediate glial cell activation, proliferation, and inflammation ([@B245]). When the PI3K/AKT/mTOR pathway is activated, the NF-κB sequestering protein IKB is released and NF-κB proinflammatory target genes are expressed, further stimulating the inflammatory pathway ([@B152]; [@B125]; [@B166]). Proinflammatory cytokines can induce the expression of iNOS or COX-2 and lead to ROS production ([@B113]). ROS cause oxidative damage that, in turn, can cause DNA damage, shortening of telomeres, increased apoptosis, and aging. A rise in ROS can lead to increased autophagy, which is consistent with the increased Aβ autophagy and dysfunctional mitochondria observed in AD patients ([@B55]). Oxidative damage results in an increase in ROS, which leads to yet further oxidative damage and feeds this self-propagating cycle ([@B55]). ROS may also trigger protein misfolding, potentially leading to protein aggregation, which is a classical hallmark of neurodegenerative diseases such as AD and PD ([@B183]; [@B269]). When cytokines, PAMPs, and DAMPs stimulate receptors such as TLR to canonically activate the NF-κB pathway, genes expressing proinflammatory cytokines are triggered, activating the nervous system's immune response ([@B123]; [@B12]; [@B47]). This leads to inflammation of the CNS, which is maintained until the brain environment reaches conditions to trigger deactivation of the immune response.

The presence of proinflammatory cytokines can also cause a shift or polarization of resting microglia to adopt their activated states. Microglial activation is routinely divided into two main phenotypes, M1 and M2, albeit that microglia can lie anywhere within the broad spectrum between these states ([@B252]; [@B180]). M1 macrophages are activated by IFN-γ, IL-6, ROS, iNOS, and TNF-α in what is referred to as classical activation. Classical activation results in proinflammatory cytokine release, lymphocyte recruitment, and a strengthened immune response. M2 macrophage activation, also referred to as alternative activation, has neurotrophic and anti-inflammatory effects and leads to tissue repair. Alternative activation occurs as a result of stimulation by IL-4/10/13, and TGF-β. The M1:M2 phenotypic ratio is greater in times of injury, and higher ratios have been associated with chronic inflammation ([@B49]; [@B12]; [@B244]).

Whereas mild levels of TNF-α and oxidative species may be neuroprotective and anti-apoptotic, excessive or prolonged neuroinflammation can be detrimental to brain health ([@B8]; [@B139]; [@B278]). In this regard, inflammation may be either protective or harmful depending on factors that include the activation cause, intensity, target, duration, transcriptional changes, and resulting intercellular activities ([@B223]; [@B87]). Additional elements such as increased blood-brain barrier (BBB) permeability along with CNS recruitment of peripheral lymphocytes can exacerbate chronic inflammation and cause a prolonged autoimmune-like response to injury ([@B113]; [@B262]). Continuous dysregulation of cytokine production can result in neurotoxicity and disrupt neural function ([@B104]).

As excessive neuroinflammation can impair neural function and induce neurotoxicity, regulating cytokines and restoring the brain microenvironment to pre-inflammatory conditions is crucial for reestablishing brain health following neural injury. Lowering and inhibiting proinflammatory cytokines, enhancing the activity of anti-inflammatory cytokines, effective phagocytic cell clearance, and selective inactivation of NF-κB can constrain inflammation and limit neuronal dysfunction and demise in neurodegenerative models ([@B12]; [@B238]; [@B124]).

The Role of Inflammation and TNF-α in Neurodegenerative Disease ([Figure 1](#F1){ref-type="fig"}) {#S3}
=================================================================================================

![Effects of TNF-α in the CNS. Inflammatory stimuli such as Aβ, α-synuclein or oxidative stress can cause neuronal death and glial cell activation, which leads to the release of inflammatory cytokines such as TNF-α. In severe cases, peripheral macrophages can infiltrate the compromised blood-brain barrier to propagate an immune response in the CNS. TNF-α activates two types of receptors- TNFR1 and TNFR2. These function differentially, with TNFR1 promoting apoptosis and activating NF-κB, which leads to proinflammatory cytokine production and glial activation, which leads to neuroinflammation and neuronal death. More glial cell activation occurs in response to this pathway, feeding the positive feedback loop of increased neuroinflammation leading to increased cell death and vice versa. On the other hand, TNFR2 activation appears largely to be neuroprotective, stimulating neurogenesis and promoting cell survival and growth ([@B44]; [@B153]).](fcell-07-00313-g001){#F1}

TNF-α is a proinflammatory cytokine produced by monocytes in the periphery and microglia, neurons, and astrocytes in the CNS ([@B46]). As a key player in inflammation, TNF-α acts as a major regulator of acute phase inflammation, initiating inflammatory cytokine signaling cascades ([@B192]). Outside of the context of injury and inflammation, a lower level of constitutively expressed TNF-α is suggested to have physiological roles affecting fetal development, cardiovascular health, and various components of the immune system, including hematopoietic cell regeneration, affecting development and homeostasis of peripheral systems ([@B99]; [@B176]; [@B258]). In the neural environment, constitutive physiological levels of TNF-α regulate synaptic plasticity, both in the context of injury ([@B151]; [@B210]), development, and homeostasis ([@B92]; [@B142]; [@B151]). TNF-α modulates dendritic maturation, pruning, and synaptic connectivity to respond to alterations in sensory stimuli to maintain homeostatic plasticity ([@B126]; [@B142]; [@B287]). One key mechanism regulating this is the cell-surface expression of AMPA receptors, a type of glutamate receptor regulating the influx of Ca^2+^ and Na^+^ in action potential initiation. AMPA receptors, whose trafficking is regulated by TNF-α, are key players in excitatory neurotransmission and long-term potentiation (LTP). Specifically, glial TNF-α has been shown to improve synaptic efficacy by increasing the cell-surface expression of AMPA receptors. Conversely, blocking TNF-α-mediated signaling has the opposite action. Notably, whereas TNF-α can adjust AMPA receptor cell surface expression, LTP and LTD are unaffected by TNF-α, but are regulated by physiological levels of the proinflammatory cytokine IL-1β. In contrast, TNF-α continuously adjusts synaptic scaling to keep the postsynaptic balance of excitatory synapses around a firing rate set point for optimal efficiency. In this manner, synaptic scaling provides a homeostatic form of synaptic plasticity, elicited to globally diminish (downscaling) or elevate (upscaling) the excitatory drive during chronic inactivity or hyperactivity, respectively, to maintain optimal neuronal performance ([@B151]; [@B210]).

In response to injury, TNF-α functions to restore brain homeostasis during acute inflammation, acting as a defensive guard to protect against CNS injury, infection, neurodegeneration, and neurotoxicity. As with excessive production of other proinflammatory cytokines, unregulated TNF-α expression contributes to chronic inflammation, glutamatergic toxicity, synaptic loss, and excessive gliosis. Chronic TNF-α expression is observed in MS, ALS, PD, ischemia, HIV-associated dementia, and AD ([@B60]; [@B118]).

All neurodegenerative diseases possess a neuroinflammatory component ([@B139]). A rise in brain TNF-α, for example, has been described across neurodegenerative disorders and may play a role in not only disease pathology and progression, but also the advancement of some of these diseases into others. An injury to the CNS in the event of a TBI can, for instance, lead to chronic inflammation that fuels Aβ misfolding and an increased risk for AD, as observed in post-mortem studies of TBI patients ([@B211]; [@B122]; [@B63]). As a prolonged or chronic inflammatory response can induce an environment that is susceptible to dysfunction, TNF-α may be an ideal drug target as a treatment strategy to mitigate neurodegenerative diseases ([@B202]).

Traumatic Brain Injury {#S3.SS1}
----------------------

In response to TBI, cell death in the meninges, blood vasculature, and parenchyma is observed in the immediate impact area ([@B64]; [@B213]). Following primary injury, secondary injury is propagated by the resulting increase in ROS ([@B100]), glutamatergic toxicity ([@B37]), and inflammation ([@B235]). Weakening of the BBB in response to injury can lead to CNS infiltration of peripheral monocytes and subsequent transformation into macrophages, as described in a study of controlled cortical impact (CCI) murine models ([@B117]).

Inflammation allows the CNS to respond to challenges such as TBI, and in ideal situations, reinstate neural function. To elucidate the role of TNF-α in TBI, TNF-α was knocked out in mice, after which cognitive performance was measured. Results showed that in the acute post-injury phase, TNF-α (−/−) mice performed better, but later, these same animals functioned worse than wildtype mice, with the TNF-α (−/−) mice exhibiting no cognitive recovery and a greater cortical injury volume ([@B223]; [@B153]). The TNF-α receptor (TNFR) has two different subtypes, TNFR1 and TNFR2, which produce different effects when activated. Activation of neuronal/microglial TNFR1 contributes to neuroinflammation and degeneration, while activation of TNFR2 largely protects against the consequences of CNS injury, such as toxic accumulation of ROS/Ca^2+^, via the NF-κB pathway ([@B17]; [@B86]; [@B44]; [@B153]). TNFR1/2 KO mice exhibit increased vulnerability to ischemia and seizure-induced neuron damage ([@B35]), indicating the need to selectively activate TNFR2 and deactivate TNFR1 at specific timepoints following injury to promote recovery.

Alzheimer's Disease {#S3.SS2}
-------------------

Alzheimer's disease is an age-related neurodegenerative disease characterized by Aβ plaque and neurofibrillary tangle formation. Aβ aggregation is initiated in the frontal neocortex, including the orbitofrontal and transentorhinal cortices ([@B30]; [@B246]), and accumulates between neurons, resulting in synaptotoxicity ([@B69]; [@B184]). As Aβ plaques can form more than a decade prior to cognitive symptom appearance in AD patients, numerous studies report tau pathology to correlate better with cognitive decline ([@B24]; [@B169]). Similar to Aβ aggregation, tau tangles begin formation in the entorhinal cortex and manifest in areas of the brain controlling higher order cognitive processes such as memory formation and decision making ([@B200]). Recent evidence suggests Aβ aggregates propagate tau tangle formation and the combined pathology of Aβ and tau aggregates lead to cognitive decline ([@B105]).

Multiple genetic and environmental factors contribute to AD risk. Some of these factors enhance neuroinflammation and hasten disease progression ([@B70]). APOE-ε4, a genetic risk factor for AD, intensifies brain atrophy. Rodents with the APOE-ε4 allele have higher proinflammatory cytokine release in response to LPS stimulation ([@B81]), indicating microglial hypersensitivity associated with the presence of APOE-ε4. Deactivation of another gene that aids in AD prevention, PIN1, leads to pTau accumulation and an increase in neuroinflammation ([@B47]). Furthermore, activated glial cells have been widely found in post-mortem brains of AD patients ([@B110]), indicating the presence of inflammation in late term AD brains.

Inflammation is also observed throughout AD progression and directly contributes to AD pathology. Early neuronal changes in AD pathology include increased production of prostaglandins, which stimulate inflammation at injury sites. Microglial activation is observed prior to cerebral neurodegeneration and astrocyte activation ([@B38]; [@B267]), and brain inflammation occurs early in preclinical AD patients ([@B178]). In middle to late stages of the disease, Aβ and pTau accumulate and astrocyte activation ensues ([@B267]). Neuroinflammation and cytokine production continue to increase as a result ([@B116]). NF-κB has been shown to regulate the transcription of BACE1, an enzyme with an essential role in APP cleavage, due to the proximity of the BACE1 promoter to several NF-κB binding sites ([@B220]). Upregulation of BACE1 leads to increased γ-secretase-mediated cleavage of APP, which leads to the generation and accumulation of Aβ (reviewed in [@B48]), which in turn leads to increased inflammation, to yield a positive feedback loop of increased pathology ([@B50]; [@B131]). There are also several signal transduction pathways linking cytokines such as TNF-α, IL-1, and IFN-γ with APP processing and subsequent Aβ plaque formation, as well as tau tangle formation ([@B97]; [@B285]; [@B230]). Due to the complex and broad impact that inflammatory processes can have in AD, theories such as the 'damage signals hypothesis' have arisen. This hypothesis theorizes that accumulation of cell stress from oxidative stress or neural injury results in long-term innate immune system activation/chronic neuroinflammation that instigates neurodegeneration, and ultimately leads to AD ([@B155]). It thereby provides a unifying mechanism to account for the diversity of risk factors that over long periods of time can bring different individuals into common pathways leading to AD.

To date, Aβ and pTau have been the most popular targets in AD drug development and research. However, emerging views of neural Aβ and pTau accumulation as disease hallmarks rather than the initial causes of AD, as well as the lack of success in AD drug development using these targets have led to a search for new drug targets. *In vivo* positron emission and single-photon emission computed tomography (PET and SPECT) scans of AD patients and AD transgenic mouse studies have pointed to neuroinflammation as a biomarker for disease progression and severity, allowing for the possibility of more accurate prediction of cognitive decline in preclinical or early AD patients ([@B101]; [@B85]). This suggests the need to look into factors of inflammation as potential therapeutic targets for AD. TNF-α, a key and initiating element in neuroinflammation, is known to activate various parts of the amyloid pathway, which underpins a key component of AD pathology. Hence targeting TNF-α, which appears to be both involved throughout both early and late stages of the cascades that trigger Aβ accumulation, may lead to a viable treatment for AD ([@B239]; [@B46]; [@B47]).

Recent research showing the positive effects of physical exercise, IL-6 supplementation, and anti-inflammatory medications to reduce TNF-α in AD models supports the premise that lowering TNF-α may mitigate or prevent AD pathology ([@B60]). In addition, the increasing number and sophistication of ligands that permit time-dependent *in vivo* imaging of microglial and astrocyte activation, whether by PET or SPECT (for review see [@B71]), together with exosome technology to quantitatively follow inflammatory proteins enriched from brain derived exosomes available in the plasma ([@B201]) have the potential to serve for early diagnosis of AD, to monitor disease progression and to test the efficacy and the most effective time window for potential anti-inflammatory treatment strategies.

Amyotrophic Lateral Sclerosis {#S3.SS3}
-----------------------------

Amyotrophic lateral sclerosis, a disease characterized by a loss of motor neurons in motor cortex, brainstem, and spinal cord, also demonstrates aspects of inflammation that may drive disease progression. Although the mechanisms through which ALS progresses remain to be more fully elucidated, mutations in ALS-associated genes such as C9orf72 or SOD1, which may activate microglia, increase risk of ALS ([@B33]; [@B138]). Activated microglia, astrocytes, and T cells have been found in all sites of motor neuron injury in ALS brains. ALS patients often generate immune responses to autoantigens, implying dysregulation of the immune system ([@B138]). In addition, the over-activation of NF-κB and resulting inflammation leads to motor neuron degeneration in ALS disease models ([@B2]; [@B191]).

Based on familial studies of ALS, C9orf72 mutations are the most common genetic cause of ALS, accounting for approximately 40% of familial ALS and 5--10% of sporadic ALS cases ([@B62]; [@B205]). C9orf72 is a protein thought to regulate endosomal trafficking ([@B77]), and its mutation was the first genetic link to frontotemporal dementia and ALS pathology. Some ALS cases have shown cognitive decline driven by TDP-43, a major source of ALS and FTD proteinopathy, and microglial activation in frontotemporal regions of the brain ([@B33]). Rodent studies have shown links between reduced expression of C9orf72 and upregulation of TREM2, a protein expressed solely in microglia within the CNS and associated with increased phagocytosis of cell debris and pathogens ([@B138]; [@B94]), leading to increased microglial activation and inflammation in the spinal cord ([@B79]). Factors in CSF from ALS patients activate rat astroglial and microglial cultures, upregulating inflammatory cytokines, downregulating neuroprotective factors, and causing neurodegeneration in cocultures containing motor neurons ([@B173], [@B174]).

There is also substantial evidence behind the role for TNF-α in ALS. TNF- α is reported to be upregulated in the blood and CSF of ALS patients ([@B11]; [@B39]), and TNFR1 and TNF-α have been found to be upregulated in the spinal cord of SOD1 mutant mice ([@B266]; [@B32]). According to genomic sequencing data, TNF-α is a major differentially expressed gene affecting protein interactions in ALS patients with C9orf72 mutations, making TNF-α a promising target for ALS treatment ([@B133]). RNA sequencing data also points to TNF-α as a major regulator of upregulated inflammatory pathways in ALS patients' spinal cords ([@B34]). Astrocyte and motor neuron cocultures from mice with mutations in genes linked to ALS, such as FUS or SOD1, demonstrate an increased release of TNF-α, leading to excitotoxicity-induced neurodegeneration. This degeneration can be blocked with TNF-α antibodies or synthesis inhibitors, such as thalidomide ([@B251]; [@B128]).

Parkinson's Disease {#S3.SS4}
-------------------

Parkinson's disease, an age-related neurodegenerative disorder, is distinguished by a progressive motor phenotype that encompasses tremors, rigidity, and bradykinesia. Neuropathologically, PD is characterized by the presence of Lewy bodies- intracellular proteinaceous inclusions that are chiefly comprised of insoluble α-synuclein aggregates. These aggregates induce deterioration of DA neurons in the *substantia nigra pars compacta* (SN) and fibers within the striatum ([@B199]; [@B170]), as well as BBB dysfunction from increased production of inflammatory cytokines such as TNF-α and IL-6 ([@B67]). Neuroinflammation is implicated in PD as seen through results of post-mortem autopsies and molecular findings. Large numbers of activated microglia are universally observed in PD patient brains post-mortem, and PD brains and CSF have elevated levels of inflammatory factors such as TNF-α, IL-1β, IL-6, and IFN-γ. Furthermore, the densest population of microglia in the brain appears to lie in the midbrain with DA neurons, which are particularly sensitive to cytokines and oxidative stress. Astrocyte exposure to α-synuclein results in astrogliosis and sensitization of the inflammatory pathway, which ultimately leads to neuronal death in neuron and astrocyte cocultures ([@B42]; [@B120]).

Neuroinflammation intensifies with disease progression ([@B163]; [@B113]), and there is a multitude of research suggesting inflammation can trigger PD pathology. Some of this research revolves around associations of immune function-related genes \[i.e., LRRK-2, HLA-DR, Nurr1 ([@B90]; [@B103]; [@B61])\] and high levels of phosphorylated α-synuclein proteins with higher risk and incidence of PD. Other theories revolve around the possibility of α-synuclein aggregating in the olfactory bulb or gut lumen due to inflammatory processes and being spread to the striatum via the olfactory tract, vagus nerve, or spinal cord through a prion-like propagation ([@B107]; [@B95]). There is also evidence of greater α-synuclein aggregation in response to oxidative stress, which induces inflammation ([@B182]; [@B227]). In this regard, PD patients may be more sensitive to chronic inflammation, as it may promote α-synuclein aggregation ([@B36]; [@B113]; [@B140]).

Several treatments focused to mitigate neuroinflammation have been shown to positively impact PD models. Early treatment with NSAIDs or other anti-inflammatory drugs has been shown to delay or prevent PD onset ([@B245]). TNF-α inhibitors have been shown to block neurotoxin-induced nigral DA neuron loss by 50% ([@B163]) and attenuate reductions in striatal dopamine in MPTP rodent models ([@B29]; [@B80]), highlighting the potential use of these agents as treatments for PD.

Multiple Sclerosis {#S3.SS5}
------------------

Multiple sclerosis is a neurological demyelinating disorder in which immune cells from the periphery infiltrate boundaries of the CNS and attack the myelin sheath coating axons, leading to myelin, axonal, and neuronal degeneration ([@B232]). The pathological basis of disease initiation remains an area of critical investigation, and it is unclear as to whether MS originates in the CNS, where degeneration of oligodendrocytes triggers activation and infiltration of peripheral immune cells, or if MS is initiated by autoimmune mechanisms within the periphery ([@B242]; [@B91]).

Microglial activation takes part in the prevention and repair of MS in its early stages, but also acts to exacerbate disease by releasing inflammatory cytokines to increase peripheral immune cell recruitment and induce demyelination ([@B204]). Of the inflammatory cytokines involved in MS progression, TNF-α has been at the forefront of MS pathology, with autopsy results showing elevated TNF-α levels in areas of active lesion formation ([@B114]). An increase in TNF-α levels in the CSF of patients with chronic progressive MS, as compared to those with stable MS, has also been observed, indicating a link between heightened TNF-α levels and MS progression ([@B231]). Reductions in proinflammatory cytokines, including TNF-α, have been shown to decrease demyelination and immune cell infiltration into the CNS in models of experimental autoimmune encephalomyelitis (EAE), one of the primary models of MS in preclinical research ([@B187]; [@B98]).

Although TNF-α blockers have shown promising results in EAE models, clinical trials of TNF-α-targeting drugs have proven to be ineffective and even detrimental in MS patients ([@B263]). There have even been reports of MS onset in TNF-α-blocker therapy for treatment of other diseases ([@B247]; [@B3]; [@B198]; [@B31]), pointing to the sensitivity of MS to levels of systemic TNF-α. These detrimental effects could be due to the non-selective inhibition of TNF-α ([@B281]; [@B240]; [@B195]; [@B222]; [@B259]; [@B84]), pointing to the need for research that elucidates the subtype and time-dependent roles of TNF-α and inflammation in pathways relating to myelination.

History and Mechanism of Thalidomide ([Figure 2](#F2){ref-type="fig"}) {#S4}
======================================================================

![**(A--C)** History of thalidomide and IMiDs. **(A)** Thalidomide discovery, market withdrawal, and repurposing ([@B233]; [@B141]; [@B264]). **(B)** FDA approval of IMiDs ([@B7]; [@B78]; [@B74]; [@B209]). **(C)** Preclinical studies using IMiDs ([@B221]; [@B54]; [@B294]; [@B15]; [@B274]; [@B59]; [@B150]; [@B216]).](fcell-07-00313-g002){#F2}

Thalidomide (α-phthalimidoglutarimide) was first marketed by Chemie-Grunenthal in 1957 under the drug name "Contergan." It was advertised as a safe, multipotent drug capable of treating symptoms ranging from anxiety to hyperthyroidism ([@B141]; [@B264]). It was prescribed to pregnant women in Europe as a well-tolerated morning sickness treatment. However, after 4 years and approximately 10,000 babies born with congenital limb deficiencies, thalidomide was taken off of the market due to its teratogenic effects ([@B162]; [@B264]).

Repurposing of the drug began more than 50 years ago as a serendipitous treatment for erythema nodosum leprosum (ENL), a skin disorder caused by leprosy ([@B233]). Since then, thalidomide has been discovered to have anti-angiogenic and anti-inflammatory properties, with the potential to treat a multitude of diseases, such as AIDS, certain cancers, and rheumatoid arthritis. Currently, it is being used to treat multiple myeloma, refractory anemia and Crohn's disease ([@B280]; [@B136]).

In 1991, thalidomide was discovered to inhibit TNF-α synthesis ([@B221]) and as a consequence, novel analogs, often referred to as IMiDs, have been synthesized and evaluated in the hope of enhancing drug potency and decreasing side effects. Thalidomide and analogs have been found to possess a broad range of actions, including anti-angiogenic, anti-proliferative, and anti-inflammatory effects ([@B290]; [Figure 3](#F3){ref-type="fig"}).

![Thalidomide mechanism of action and pleiotropic effects: Following introduction of cell stressors such as inflammatory cytokines or pathogens, the NF-kB transcription factor is activated, leading to increased transcription and translation of TNF-α. Thalidomide binds to the 3′-UTR of TNF-α mRNA, leading to mRNA destabilization and inhibiting TNF-α cytokine production. Thalidomide has anti-angiogenic ([@B57]; [@B290]) and anti-proliferative ([@B9]; [@B290]; [@B167]) properties, inhibiting tumor growth, and making it a promising candidate for cancer treatment. Thalidomide also possesses anti-inflammatory ([@B221]; [@B290]; [@B76]) properties, which have the potential to be used in inhibiting inflammation contributing to neurological disease. Thalidomide has differential roles in the periphery versus the CNS, activating anti-apoptotic ([@B15]; [@B76]; [@B253]) pathways in neurons and pro-apoptotic ([@B175]; [@B93]) in monocytes.](fcell-07-00313-g003){#F3}

In the periphery, thalidomide has anti-angiogenic and anti-proliferative properties ([@B9]), making it a potential drug for treatment of diseases such as cancer ([@B57]). Thalidomide was FDA approved to treat refractory multiple myeloma in 2013 due to its induction of apoptosis of myeloma cells and ability to inhibit bone marrow support to myeloma cells by impairing cell adhesion ([@B175]; [@B261]). Thalidomide also has analgesic properties shown in models of neuropathic pain, attributed to its ability to attenuate TNFR expression ([@B6]).

Within the CNS, thalidomide has been shown to reduce the generation and secretion of inflammatory cytokines such as IL-1, IL-6, IL-8, IL-12, GM-CSF and TNF-α ([@B261]; [@B156]). The drug downregulates NF-κB in activated B cells ([@B127]; [@B284]; [@B193]; [@B144]) and degrades TNF-α mRNA by altering it at its 3′-UTR (untranslated region) to destabilize the cytokine post-transcriptionally, ultimately shortening its half-life ([@B179]; [@B294]; [Figure 3](#F3){ref-type="fig"}). With lower TNF-α levels, proinflammatory cytokine production is inhibited, and neuroinflammation is reduced. Thalidomide has also been shown to have anti-oxidative and anti-apoptotic effects in stroke and TBI models ([@B76]; [@B253]).

Although thalidomide derivatives have varying properties and potencies, they all appear to lower TNF-α. A breakthrough in understanding potential mechanisms underpinning thalidomide and related IMiDs is that some appear to bind to cereblon, a critical component of an E3 ubiquitin ligase complex with an intermediary role in immunomodulation ([@B167]; [Figure 4](#F4){ref-type="fig"}). In the context of multiple myeloma, thalidomide analogs cause cereblon to interact with associated factors to form a ligase that breaks down Ikaros (IKZF1) and Aiolos (IKZF3), two members of the Ikaros family of zinc finger transcription factors important in B-cell development ([@B134]). The protein degradation abilities of thalidomide via its interactions with cereblon have been an emerging topic of interest in the field of drug development ([@B282]; [@B5]). However, the implications and detailed mechanism of cereblon interactions with thalidomide's anti-inflammatory response remain unclear ([@B171]). It is quite possible that IMiDs have both cereblon-dependent and independent mechanisms that impact TNF-α and its multiple associated proteins in neuroinflammation, as not all IMiDs with TNF-α inhibiting properties have cereblon binding potential ([@B172]; [@B171]). It is clear, however, that cereblon and IKZF1/3 are expressed within the brain and are associated with learning and memory, with mutations in cereblon posing a risk for intellectual disabilities ([@B112]; [@B41]). Interestingly, in an integrated multi-cohort transcriptional meta-analysis of neurodegenerative diseases in which genes associated with M1-polarized macrophages/microglia and reactive astrocytes were strongly enriched, IKZFI was identified across all of the neurodegenerative disorders evaluated ([@B145]). Thalidomide has also shown anticonvulsant actions in seizure models of mice, possibly through the inhibition of iNOS ([@B194]), which, likewise, has a role in inflammation ([@B157]).

![Protein degradation mechanism of Thalidomide via cereblon-binding: Thalidomide is composed of glutarimide and phthalimide moieties, which interact differentially with various targets. The glutarimide ring binds cereblon to create an E3 ubiquitin ligase complex ([@B167]), while phthalimide targets non-cereblon proteins ([@B185]). The formation of an E3 ubiquitin ligase complex leads to protein degradation ([@B282]; [@B5]), which underlies the ability of IMiDs to treat multiple myeloma ([@B134]) and potentially other diseases in which protein aggregation or malfunction play a role. The exact mechanism of TNF-α inhibition by IMiDs is yet to be elucidated, but is likely to be a combination of effects of both glutarimide and phthalimide moieties ([@B224]; [@B171]; [@B43]). CRBN, Cereblon; DDB1, DNA damage-binding protein 1; CUL4, Cullin-4; ROC1, Regulator of Cullins-1.](fcell-07-00313-g004){#F4}

Clinical Trials of Thalidomide and Its Analogs in Neurodegenerative Disease {#S5}
===========================================================================

Thalidomide and its analogs have and are continuing to be evaluated in clinical trials that have led to the repurposing of IMiDs for diseases such as multiple myeloma. Thus far, the majority of research and clinical trials performed on novel thalidomide derivatives have related to peripheral diseases. The few trials that have had CNS disease targets ([Table 1](#T1){ref-type="table"}) have focused on the anti-angiogenic properties of IMiDs. For instance, NCT02415153 is a phase I trial in which the tolerability and best dose of pomalidomide in treating younger patients with persistent tumors of the brain or spine are being studied. NCT01553149 is a phase II trial that compares the effects of low and high doses of lenalidomide in treating younger patients with juvenile pilocytic astrocytomas or recurrent, refractory, or progressive optic nerve pathway gliomas.

###### 

Clinical trials of Thalidomide and its FDA approved analogs relating to neurological disorders.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Candidate**   **Condition**                         **[ClinicalTrials.gov](https://clinicaltrials.gov/) Identifier(s)**   **Clinical phase**   **Results**
  --------------- ------------------------------------- --------------------------------------------------------------------- -------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Thalidomide     Amyotrophic Lateral Sclerosis (ALS)   NCT00231140,\                                                         Pilot, Phase II      Study was terminated due to bradycardia occurrence as a common adverse effect ([@B168]); no significant improvement in function or cytokine profile following 9 months of treatment ([@B241]).
                                                        NCT00140452                                                                                

  Thalidomide     Arachnoiditis                         NCT00284505                                                           Phase II             Unavailable

  Thalidomide     Epilepsy                              NCT01061866                                                           Phase I, II          The mean number of seizures in the patients tested decreased from 27 ± 4 to 7 ± 1 seizures per month, showing a high therapeutic potential for thalidomide on refractory seizures ([@B190]).

  Thalidomide     CNS tumor and metastases              NCT00049361,\                                                         Phase I, II, III     No beneficial effect of thalidomide on CNS metastases was observed. In a trial with thalidomide treatment combined with radiation therapy (NCT00049361), nearly half of the thalidomide treatment group discontinued treatment due to side effects ([@B132]). When given in conjunction with radiation therapy and temozolomide, efficacy was low ([@B10]; [@B196]) (NCT00112502). Some trials are ongoing (NCT00179881) or have no reported results.
                                                        NCT00527657,\                                                                              
                                                        NCT00039468,\                                                                              
                                                        NCT00179881,\                                                                              
                                                        NCT00098865,\                                                                              
                                                        NCT00006358,\                                                                              
                                                        NCT00079092,\                                                                              
                                                        NCT00014443,\                                                                              
                                                        NCT00112502,\                                                                              
                                                        NCT00047281,\                                                                              
                                                        NCT00047294                                                                                

  Thalidomide     Adrenoleuko- dystrophy                NCT00004450                                                           Orphan study         Immunosuppressive drugs combinations had no beneficial effect on patients ([@B27]).

  Thalidomide     Alzheimer's Disease                   NCT01094340                                                           Phase II, III        Thalidomide was poorly tolerated by trial participants, preventing patients from reaching the target dose of thalidomide and causing patients to drop out of the study prematurely ([@B59]).

  Lenalidomide    CNS tumor                             NCT00036894,\                                                         Phase I, II          Lenalidomide proved to be well tolerated in CNS tumor patients ([@B82]) (NCT00036894), and was found to have antitumor activity in pediatric CNS tumor patients ([@B276]) (NCT00100880). Some trials are ongoing (NCT01553149, NCT03703167) or have no reported results.
                                                        NCT03050450,\                                                                              
                                                        NCT01553149,\                                                                              
                                                        NCT00100880,\                                                                              
                                                        NCT0370316,\                                                                               
                                                        NCT03558750                                                                                

  Lenalidomide    POEMS Syndrome                        NCT00971685,\                                                         Phase II             Lenalidomide treatment in conjunction with dexamethasone significantly relieved symptoms of POEMS, such as extravascular volume overload, organomegaly, and pulmonary hypertension ([@B143]) (NCT01816620). NCT02921893 is ongoing, but preliminary data suggests ixazomib, dexamethasone, and lenalidomide combination therapy is effective at treating POEMS syndrome ([@B66]).
                                                        NCT01816620,\                                                                              
                                                        NCT02193698,\                                                                              
                                                        NCT02921893                                                                                

  Lenalidomide    Neuropathy                            NCT00665652                                                           Phase II             Trial was terminated due to unexpected paraproteinemia side effect ([@B52]).

  Pomalidomide    CNS tumor                             NCT02415153,\                                                         Phase I, II          Pomalidomide treatment of children with CNS tumors failed to meet clinical significance ([@B75]). NCT03798314 is ongoing.
                                                        NCT03257631,\                                                                              
                                                        NCT03798314                                                                                
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

However, these drugs have yet to be evaluated systematically in subjects of neurodegenerative disease. Thus far, thalidomide has been tested in ALS patients in 2 studies. One study (NCT00231140) was terminated prematurely due to safety concerns regarding a common sinus bradycardia effect in the patients ([@B168]). Another study (NCT00140452) observed primarily adverse effects and no improvement in treated subjects ([@B241]). Thalidomide has also been tested in AD patients, but no differences in BACE1, a genetic measure of AD severity, were observed and 14 out of 25 patients dropped out of the trial due to adverse drug effects ([@B59]), preventing the trial from administering the necessary dose to see an efficacious response (NCT01094340). Although thalidomide trials of neurological diseases have been unsuccessful to date, forthcoming trials should be focused on more potent new generation IMiDs in treating neurological diseases as, clearly, improvements over thalidomide need to be made in new analogs before they can be used to effectively treat neuroinflammation. Drug dose adjustment to mitigate toxicity and enhance potency via an increased understanding of drug-to-target attraction and bioavailability should be made for future clinical studies. As an example of the latter, lenalidomide distribution into brain is surprisingly low, in contrast to thalidomide ([@B215]). Whereas the structure and lipophilicity of lenalidomide and thalidomide are similar, a recent study suggests that the former is a substrate of the efflux transporter, *P*-glycoprotein ([@B115]), which actively removes select compounds from the brain as part of the BBB ([@B73]). Future research focused on separating the anti-inflammatory from the primary adverse effects of IMiDs could potentially lead to repurposing of thalidomide analogs as treatments for neurodegenerative diseases such as AD, PD, ALS, or TBI.

Advantages of Thalidomide Derivatives Over Other Drugs {#S6}
======================================================

Thalidomide analogs such as lenalidomide and pomalidomide are the lead IMiDs being tested in clinical trials ([@B18]). One advantage of thalidomide is its high bioavailability (90% after oral dosing) and distribution to the brain (brain/plasma ratio 0.89 in rodent studies ([@B119]), CSF/plasma ratio 0.42 in non-human primates ([@B181]). As noted, a key mechanism by which thalidomide inhibits TNF-α production is post-transcriptionally via mRNA degradation ([@B179]; [@B214]). TNF-α levels, like other proteins, are regulated both transcriptionally and post-transcriptionally. However, under healthy control conditions the translation of TNF-α mRNA into protein is highly repressed via RNA-binding proteins and miRNAs that interact with AREs within the 3′-UTR of TNF-α ([@B161]). This translational control provides a tactical benefit for cells, such as microglia, that generate and release proteins that have a physiological role (at routine low levels) and an immune role (at high concentrations), allowing a rapid change in roles through the use of pre-existing mRNAs to sidestep the lengthy nuclear control mechanisms (i.e., transcription, splicing, and transport). Simultaneously, it affords the equally rapid reversibility through modifications (e.g., reversible phosphorylation) of the regulatory intermediates. Collectively, this permits rapid activation or cessation of synthesis of a specific protein required for inflammation. Hence, in response to LPS or a similar challenge, a 3 to 4 log (1000 to 10,000-fold) increase in TNF-α protein secretion can be swiftly delivered by removal of the translational blockade and concurrent activation of transcription. A group of RNA-binding proteins are recruited to the ARE within the 3′-UTR of TNF-α that, collectively, stringently regulate translation. These include the RNA stabilizing protein HuR, heterogeneous nuclear ribonucleoprotein (hnRNP)-A1, T cell intracellular Ag (TIA)-1, TIA-1--related protein, AUF1 and tristetraprolin (TTP). For example, hnRNP-A1 binding to the ARE element represses TNF-α mRNA basal translation, and subsequent phosphorylation of hnRNP-A1 by Mnk, a kinase downstream of p38 MAPK, lowers its affinity for the ARE and, thereby, restores TNF-α translation ([@B161]). Likewise, TTP and AUF1 both destabilize TNF-α mRNA and thus reduce its translation into protein ([@B292]; [@B137]). Both these RNA-binding proteins appear to be regulated by p38 MAPK, and p38 MAPK has been shown to be inhibited by thalidomide ([@B186]) -- providing one of likely several mechanisms via which thalidomide and similar IMiDs regulate TNF-α levels. As TNF-α expression has been shown to be upregulated in models of neurological disease ([@B49]; [@B34]; [@B147]), supporting the need to target TNF-α to decrease neuroinflammation accompanying neurodegeneration, the high brain penetrance of thalidomide and analogs together with an ability to repress TNF-α at the level of its synthesis, provides a promising approach to mitigate neuroinflammation.

Support of TNF-α as a drug target for neurodegenerative disorders is provided by etanercept (Enbrel^®^) and infliximab (Remicade^®^). These TNF-α specific monoclonal antibodies and recombinant fusion proteins are widely used TNF-α modulators that have proven to be highly effective against a broad number of inflammatory-mediated diseases, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, plaque psoriasis and ankylosing spondylitis (for review see [@B229]; [@B177]), and have been applied to neurological disorders. By acting as a false target and binding to soluble and membrane-bound TNF-α, these biologicals prevent TNF-α from interacting with its receptors, thereby precluding ligand triggered TNFR signaling. The application of the anti-TNF-α antibody chimeric monoclonal antibody approach to neurodegenerative disorders was pioneered by [@B248], [@B249]. In a 6-month open AD trial, etanercept administration demonstrated significant improvements in dementia patients ([@B250]), whereas infliximab has been reported to improve cognition in an AD case study ([@B234]), providing positive preliminary data that warrants support to follow up in a double blind study. Notably for systemic disorders like rheumatoid arthritis, both etanercept and infliximab require intravenous or subcutaneous injection for routine administration as they are biologicals that possess a low bioavailability and are subject to degradation if taken orally. As protein therapeutics, they have strictly limited BBB penetration, and are hence best administered by perispinal injection paired with Trendelenburg positioning- a head-down tilt placing to attempt to facilitate drug delivery into the CSF following their distribution into the cerebrospinal venous system ([@B257]; [@B248], [@B249]; [@B243]; [@B47]).

In contrast and as noted, thalidomide, is orally active, has a high bioavailability and readily permeates the BBB, allowing for its easy and less invasive administration. Studies comparing etanercept, infliximab, and thalidomide treatments are rare, but a preclinical one exists in a STZ-induced dementia rat model that demonstrated the efficacy of all three treatments to mitigate neurodegeneration. Thalidomide was favored as the treatment group by the studies' authors as it demonstrated a trend for lowest neuritic plaque formation ([@B135]).

A promising feature of the above approaches is their pleiotropic nature, as TNF-α is tied into multiple signaling pathways that impact key mediators on inflammation. Unfortunately, TNF-α lowering agents are not a magic bullet for all inflammatory disorders. Adverse events can be severe in some patients. For anti-TNF-α antibodies, infections can develop, up to 20% of subjects do not initially respond to therapy, and immunogenicity can occur that leads to a lack of response in up to 46% of patients over 12 months of treatment ([@B26]). In contrast, IMiDs are known to be teratogenic and therefore cannot be prescribed to women who are pregnant or who may become pregnant during therapy. Thalidomide is associated with neutropenia, leukopenia and lymphopenia at high doses as well as with peripheral neuropathy and somnolence. Nevertheless, the repurposing or repositioning of a drug, if efficacious and tolerable, can be beneficial as it can lead to a rapid disease treatment with limited resources and/or a proof of mechanism study that, if positive, can then open up a new and focused drug development. The cost of clinical trials to demonstrate safety and efficacy of an original drug can take up to 15 years and \$2.6 billion ([@B65]). In comparison, repurposing an existing drug provides an accelerated route in light of its known clinical safety and pharmacokinetic data -- resulting in substantially lower costs \[as low as \$8.4 million and 3--12 years ([@B1]; [@B111])\] and a lower rate of attrition. As a pertinent example, thalidomide was successfully repurposed by Celgene for the treatment of a broad number of systemic inflammatory disorders and cancers. Thus far, however, the preclinical promise of thalidomide in animal models of neurodegeneration has not translated into clinical efficacy ([@B168]; [@B241]; [@B59]) as sufficient CNS TNF-α and anti-inflammatory action appears unachievable in the absence of dose-limiting adverse effects. This, amongst other factors, provides a basis of evaluating both existing and new analogs that may pair higher potency with greater tolerability.

Current Research Surrounding Thalidomide Analogs {#S7}
================================================

Thalidomide has been modified to form several analogs, some of which have been widely tested for efficacy in treating various cancerous and immunological diseases. These new analogs have been generated to provide more TNF-α inhibition, a broader range of activities and, in some cases, a high BBB penetrance ([@B54]; [@B257]).

Not all thalidomide analogs have the same properties; for instance, analogs such as apremilast are PDE inhibitors, while others are not. While non-PDE inhibiting analogs stimulate T cells, IL-2, and IFN-γ production, PDE inhibiting analogs have little effect on peripheral T cells ([@B53]; [@B159]).

Thalidomide (THALOMID^®^) and First Generation of IMiDS (1996--1998; [Figure 5](#F5){ref-type="fig"}) {#S7.SS1}
-----------------------------------------------------------------------------------------------------

![Chemical structures of thalidomide and its analogs.](fcell-07-00313-g005){#F5}

Currently, thalidomide is used in the treatment of a broad number of inflammatory disorders such as Crohn's disease, arthritis, ulcerative colitis, ENL, multiple myeloma, and dermal conditions involved with Behcet's disease, as well as some types of cancers ([@B233]; [@B279]; [@B106]; [@B78]). Additionally, as already noted, due to its multipotent characteristics, thalidomide has been evaluated for repurposing across numerous neurological disorders.

In preclinical studies, both short-term and long-term thalidomide treatment of AD rodents led to decreases in overall disease pathology, neuroinflammation, and cognitive impairment ([@B108]; [@B135]). Thalidomide has also been shown to have anti-apoptotic effects in stroke models *in vitro* and *in vivo*. These effects are likely due to thalidomide's induction of phosphorylated Akt and activation of the pro-growth PI3K/Akt pathway, which potentially counter the apoptotic effects associated with AD and stroke. Thalidomide's protection against oxidative stress may also play a part in offsetting neuronal damage ([@B121]; [@B291]; [@B76]). Thalidomide has also shown promise in patients with blindness rising from TBM, with case studies of multiple patients being completely cured of blindness from a reduction of inflammation ([@B212]; [@B226]). However, a pilot study of thalidomide treatment in children with TBM was terminated due to adverse effects ([@B225]).

To create the first generation of IMiDs, imide carbonyl groups of the thalidomide backbone were thionated in specific key positions. The resulting thiothalidomide analogs possess enhanced TNF-α inhibition, with di- and tri-thionated species demonstrating enhanced anti-TNF activity relative to standard thalidomide ([@B294]). TNF-α lowering potency increased with the number of thions added to the glutarimide backbone, with trithiothalidomide decreasing TNF-α levels 30-fold more effectively than thalidomide ([@B96]; [@B256]).

3,6′-Dithiothalidomide (3,6′-DT), a compound developed and evaluated within our laboratory, demonstrated a decrease in microglial activation, TNF-α levels, and chronic inflammation in LPS-induced cell and rat models. In rats, treatment restored cognitive function and normalized plasticity-mediating gene expression in the hippocampus ([@B25]).

In mild TBI (mTBI) models, 3,6′-DT ameliorated all effects of injury in mice when treatment was administered from 1 to 12 h post-injury. These effects involved reversal of mTBI-induced decreases in cognitive function, increases in activated astrocytes, neuronal loss, increased TNF-α, and increased apoptosis in a mouse model of concussive injury ([@B14], [@B15]). These actions translated to a moderate to severe rat model of TBI in which 3,6′-DT significantly reduced contusion volume, neuronal degeneration, neuronal apoptosis and neurological deficits when administered within 5 h of injury, substantially lowering pro-inflammatory cytokines at the transcription and translation level, and suppressing neuronal markers of oxidative stress ([@B20]).

In AD mouse models of stereotaxic intracerebroventricular Aβ~1-42~, 3,6′-DT ameliorated Aβ-induced neuroinflammation and microglial activation, prevented neurodegeneration, and improved memory ([@B217]). In 3xTg (APP~Swe~/PS1~M146V~/tau~P301L~) AD mice, long term thalidomide or 3,6′-DT treatment stabilized TNF-α gene expression and protein levels to WT levels. However, thalidomide treatment failed to prevent cognitive decline in 3xTg mice's working memory, whereas 3,6′-DT treatment successfully achieved this. Furthermore, only 3,6′-DT treatment increased the ratio of resting and activated microglia, which is associated with neuroprotection ([@B87]). 3,6′-DT treatment of 3xTg AD mice also resulted in lower hippocampal Aβ levels, tau deposits, and improved cognition ([@B87]; [@B255]).

In focal ischemic stroke mouse models, 3,6′-DT proved to be efficacious when administered 1--3 h post-stroke to reduce neuronal loss, inhibit TNF-α, IL-1β, iNOS, and apoptosis, whereas thalidomide showed no significant effect. Notably, TNFR KO mice were not rescued with 3,6′-DT post-injury, consistent with a critical role for the suppression of TNF-α production and TNF-α signaling in the therapeutic action of 3,6′-DT, and the value of potent TNF-α suppressing agents to restrain microglial activation and inflammation ([@B288]). In separate studies, 3,6′-DT treatment of mice post-hypoxia or blast injury attenuated injury-related increases in TNF-α and changes in synaptic transmission ([@B272]; [@B275]), thereby, cross-validating the suppression of TNF-α generation and release to mitigate inflammation-mediated neuronal damage across animal models of CNS injury. Finally, in a recent study, both 3,6′DT and thalidomide were demonstrated to mitigate the severity of [L]{.smallcaps}-dopa-induced dyskinesia in nigrostriatal-lesioned rat models of PD, suppressing both microgliosis and elevated TNF-α in the striatum and substantia nigra, and restoring IL-10 anti-inflammatory cytokine levels ([@B28]).

Second Generation -- Lenalidomide (REVLIMID^®^) (FDA Approved 2006; [Figure 5](#F5){ref-type="fig"}) {#S7.SS2}
----------------------------------------------------------------------------------------------------

Lenalidomide, marketed as Revlimid by Celgene, is an analog of thalidomide with an amino group on the C4 position of the benzene ring system. Cellular studies have shown lenalidomide to activate T cells, suppress angiogenesis, and modulate inflammation by decreasing cytokines ([@B165]). The drug induces M2 polarization of macrophages by upregulating IL-10 and activating STAT3, acting against inflammation to promote survival in MS models ([@B277]). It also downregulates inflammation-related miRNA in astrocyte cultures stimulated with LPS and MRP8 ([@B188]). Lenalidomide has also been reported to be 2,000-fold more potent than thalidomide in inhibiting TNF-α secretion from monocytes ([@B261]). Lenalidomide treatment of ALS transgenic mice resulted in enhanced motor performance, decreased motor neuron death, and increased life span ([@B129]). Lenalidomide and, in particular, combination therapy with ROS scavenger Nanoceria were shown to ameliorate cognitive decline, CNS myelin loss, ventricular volume enlargement, neuroinflammation, and white matter damage in a MS model in mice ([@B72]). Thalidomide and lenalidomide have also been shown to reduce microgliosis and NF-κB activation, motor deficits, and excitotoxicity and DA fiber loss in the striatum of PD mouse models ([@B189]; [@B260]), supporting the potential use of IMiDs as a treatment for PD.

Lenalidomide was approved by the FDA in May 2006 for combination treatment with dexamethasone for relapsed or refractory multiple myeloma, and has undergone clinical trials for an increasing number of solid tumor malignancies, including prostate cancer, melanoma, and glioma ([@B7]). It was also approved to treat myelodysplastic syndromes in 2005 ([@B148]; [@B165]). The drug is currently in a phase 2 trial for relapsed CNS myeloma treatment ([@B216]), and appears to have fewer adverse effects compared to thalidomide in the treatment of multiple myeloma. Notably, thalidomide's often prominent side effects of constipation, peripheral neuropathy, and drowsiness, were not observed in lenalidomide clinical trials ([@B207]), suggesting that these may not necessarily be drug-class dependent. Lenalidomide was determined to be safe in clinical trials for refractory melanoma, with T-cell stimulatory effects in cancer patients ([@B19]). However, its association with increased risk for stroke was recently observed in multiple myeloma patients ([@B58]). Although lenalidomide is not associated with the level of neurotoxicity that accompanies thalidomide (where peripheral neuropathy is reported in up to 83% of myeloma patients, [@B56]), with the longer use of lenalidomide reports of neurotoxicity -- albeit milder than thalidomide and sometimes subclinical -- are appearing in the literature ([@B56]). In contrast, venous thromboembolism has emerged as lenalidomide's most common side effect ([@B18]; [@B165]), which may potentially be reduced when used in combination therapy with aspirin ([@B22]).

There is limited information in relation to the utility of lenalidomide in neurodegenerative disorders, but its evaluation in a PD α-synuclein mouse model demonstrated promising activity. It reduced motor behavioral deficits and mitigated DA fiber loss in the striatum. Microgliosis was decreased in both the striatum and hippocampus, and pro-inflammatory cytokines expression levels were decreased leading to a reduction in NF-κB activation ([@B260]).

Third Generation -- Pomalidomide (POMALYST^®^) (FDA Approved 2013; [Figure 5](#F5){ref-type="fig"}) {#S7.SS3}
---------------------------------------------------------------------------------------------------

Pomalidomide, marketed by Celgene under the name Actimid, is one of the most potent thalidomide derivatives to be discovered thus far. In a rat model of moderate to severe TBI, pomalidomide treatment ameliorated injury-induced neurodegeneration, apoptosis, cognitive decline, and proinflammatory cytokine upregulation when given up to 5 h post-injury. The same effects were observed in primary microglia and cortical cell cultures challenged with glutamate in a dose-dependent manner ([@B273]). As shown in oxidative stress models, pomalidomide has neuroprotective and antioxidative effects mediated by Nrf2/SOD2/catalase pathways ([@B253]). Finally, a recent study has demonstrated the activity of pomalidomide post-injury administration in a rat model of ischemic stroke, reducing the cerebral infarct volume and mitigating functional deficits ([@B254]). A recent novel compound of interest, 3,6′-dithiopomalidomide (3,6′-DP), combines the advantages of thionation evident in 3,6′-DT on the thalidomide backbone into third generation pomalidomide. Preliminary studies demonstrate the potent action of 3,6′-DP in rodent TBI at one fifth of the efficacious dose of pomalidomide, and further results in other neuroinflammatory cellular and animal models are awaited with interest.

As noted earlier, recent studies have shown that IMiDs, excluding apremilast, bind to cereblon. Cereblon interacts with the DNA damage-binding protein-1 (DDB1), Cullin 4 (Cul4A or Cul4B), and regulator of Cullins 1 (RoC1) to create the functional E3 ubiquitin ligase complex. Within this ligase complex, cereblon acts as a substrate receptor to target select proteins for proteolysis via a ubiquitin-proteasome pathway ([@B236]). Cereblon appears to be one of many substrate receptor proteins that can be recruited into the E3 ubiquitin ligase complex to allow it to target different substrates. In this regard, IMiDs have been reported to form a molecular bridge between cereblon, within the E3 ubiquitin ligase complex, and its target protein to destine it for proteasome degradation. The glutarimide moiety of the IMiD binds cereblon, and the phthalimide moiety binds to the target proteins ([@B40]; [@B83]). Known targeted proteins, such as IKZF1/3, are predicted to possess a β-hairpin motif that comes into contact with the phthalimide structure ([@B197]). Thalidomide, lenalidomide, or pomalidomide treatment hence leads to diminished levels of IKZF1/3, and likely other select proteins, which causes upregulation of IL-2 and activates T cells ([@B106]; [@B89]). Pomalidomide appears to be the most potent with regards to T cell co-stimulation, but appears to have similar anti-angiogenic activity to that of lenalidomide ([@B19]). Pomalidomide effectively modulates tumorigenesis and angiogenesis, making it a favorable drug for use in cancer treatment. It has been approved for use in multiple myeloma patients for whom lenalidomide and bortezomib have failed to prevent disease progression ([@B209]).

Fourth Generation -- Apremilast (Otezla^®^) (FDA Approved 2014; [Figure 5](#F5){ref-type="fig"}) {#S7.SS4}
------------------------------------------------------------------------------------------------

Apremilast was FDA approved to treat moderate to severe cases of plaque psoriasis and psoriatic arthritis in 2014 ([@B74]). Similar to other IMiDs, apremilast inhibits TNF-α protein synthesis. However, as noted previously, the drug acts via PDE4 inhibition, upregulating cAMP and thereby reducing proinflammatory cytokine production. Although apremilast is effective in treating peripheral inflammation, it has poor brain penetrance, as shown in *in vivo* pharmacokinetic studies using radioactivity to measure drug levels in the brain ([@B51]). LogP values of apremilast and other thalidomide analogs indicate apremilast has higher lipophilicity than other IMiDs, and its molecular size (460.5 Da) and general features are within the range of molecules that can cross the BBB ([Table 2](#T2){ref-type="table"}). However, *in vitro* confirmation of apremilast as a P-glycoprotein substrate, the low CNS MPO Score of apremilast in comparison to other IMiDs ([Table 2](#T2){ref-type="table"}), and its low brain/plasma concentration ratio of ≤0.1 in pharmacokinetic studies ([@B51]) support its lack of potential as an active drug for CNS disorders. There do not currently appear to be any literature reports of apremilast evaluation in animal models of neurodegeneration.

###### 

Factors of drug pharmacokinetics at physiological conditions.

  **Drug name**                **Molecular weight (g/mol)**   **cLogP**   **cLogD (pH7.4)**   **Number of Hydrogen bond donors**   **Number of Hydrogen bond acceptors**   **Topological polar surface area (Å^2^)**   **Strongest basic pK~a~ calculation**   **CNS MPO Score**
  ---------------------------- ------------------------------ ----------- ------------------- ------------------------------------ --------------------------------------- ------------------------------------------- --------------------------------------- -------------------
  Thalidomide                  258.2                          0.02        0.02                1                                    4                                       83.55                                       11.59^∗^                                4.8
  3,6′-Dithiothalidomide       290.4                          1.80        1.79                1                                    2                                       49.41                                       9.8^∗^                                  4.9
  Lenalidomide                 259.3                          --0.71      --0.71              2                                    4                                       92.50                                       2.31                                    5.4
  Pomalidomide                 273.2                          --0.16      --0.16              2                                    5                                       109.57                                      1.56                                    4.8
  3,6′-Dithiopomalidomide      305.4                          0.97        0.96                2                                    3                                       75.43                                       2.33                                    5.5
  Apremilast                   460.5                          1.31        1.31                1                                    7                                       119.08                                      12.98^∗^                                3.1
  Adamantyl phthalimidine      295.4                          3.86        3.86                0                                    1                                       20.31                                       --1.04                                  3.7
  Noradamantyl phthalimidine   253.3                          2.75        2.75                0                                    1                                       20.31                                       --0.85                                  4.7

Molecular weight, cLogP/D value, number of Hydrogen bond donors/acceptors, topological polar surface area, and pK

a

were generated using Chemicalize for several IMiDs, including a recent pomalidomide derivative of interest- 3,6′-dithiopomalidomide (3,6′-DP). IMiDs generally follow the Lipinski rule of five, which predicts the likelihood of a drug being delivered to its target in human physiological conditions based on its physical properties (

Banks and Greig, 2019

). A CNS MPO Score, which predicts drug BBB permeability, was calculated using parameters and functions described by

Wager et al. (2010)

. Higher CNS MPO Score correlates with greater drug BBB permeability.

∗

Indicates the calculated strongest acidic pK

a

value used to calculate CNS MPO Score when the calculated strongest basic pK

a

value was not provided in Chemicalize calculations. Calculated acidity values are not necessarily representative of the neutral parent compound and may instead reflect the pK

a

of a corresponding protonated species.

Adamantyl and Noradamantyl Phthalimidines ([@B154]; [Figure 5](#F5){ref-type="fig"}) {#S7.SS5}
------------------------------------------------------------------------------------

Adamantyl groups can be added to drugs to increase lipophilicity, drug stability, and plasma half-life ([@B149]). Adamantyl groups also strengthen molecule interactions with CNS targets, allowing development of more efficient drugs. For instance, iron chelator Desferrioxamine B (DFOB), which was seen to be effective in PD cell and animal models, was conjugated with adamantane and increased 66-fold in efficacy ([@B146]). Likewise, many neuroprotective drugs such as memantine, one of the only drugs approved to treat AD, and amantadine, which is used to treat Parkinson disease, contain adamantyl groups ([@B203]; [@B219]). Another adamantyl derivative, *N*-adamantyl-4-methylthiazol-2-amine (KHG26693), suppresses oxidative damage caused by Aβ and LPS-induced increases in proinflammatory cytokines by suppressing NF-κB ([@B45]; [@B130]).

Our laboratory synthesized 15 novel IMiDs featuring adamantyl and noradamantyl phthalimidines. As noted earlier, the glutarimide and phthalimide moieties of thalidomide and analogs interact with cereblon and its targeted proteins, respectively, and modifications in these moieties could potentially influence the affinity and selection of targeted proteins ([@B289]). These 15 compounds have been shown to have nitrite and TNF-α lowering activity. The degree of nitration of adamantyl phthalimidines has also been shown to affect drug efficacy, with higher nitration yielding greater anti-nitrite activity ([@B154]). Interestingly, in a broader series of novel IMiDs likewise synthesized within our laboratory in which both small and substantial modifications were introduced into the glutarimide and phthalimide moieties, the resulting agents demonstrated a range of pharmacological actions ([@B23]). Cohorts of compounds expressed anti-angiogenic properties, others anti-inflammatory properties and some exhibited both, thereby, allowing the separation of these and likely other actions. Compounds from these series are now being evaluated in animal models of neurodegeneration, and results are awaited with interest.

Considerations Prior to IMiD Clinical Trials for Neurodegenerative Disease {#S8}
==========================================================================

Although thalidomide analogs are promising, there are still negative findings and drug adverse effects that must be addressed prior to its use for targeting inflammation in neurodegenerative disease.

First, thalidomide appears to be a pleiotropic drug, affecting multiple biological pathways upon entering the circulatory system. Although the multipotency of thalidomide gives the drug potential to treat a multitude of symptoms via many positive pathways, it also increases the risk for drug side effects. For instance, thalidomide has been very effective in healing orogenital ulceration via its anti-inflammatory effects while simultaneously inducing or exacerbating erythema nodosum via its T-cell costimulatory effects in Behcet syndrome patients ([@B102]). Thalidomide's co-stimulation of T-cells has also been observed in a clinical trial of thalidomide in HIV patients ([@B53]; [@B268]), pointing to the possibility of thalidomide inducing inflammation in immunocompromised individuals. The mechanisms underlying other adverse actions, such as the teratogenic effect, have yet to be fully characterized but are postulated to consist of a combination of thalidomide/metabolite interactions with the bodily environment, including thalidomide binding with cereblon, which yields angiogenesis inhibition ([@B264]). Additionally, recent research reveals that thalidomide interacts with cereblon to target and repress SALL4, a key transcription factor of the Spalt-like family with a critical role in embryonic limb development ([@B68]; [@B160]; [@B265]). Interestingly, nitric oxide has been shown to diminish thalidomide-induced teratogenicity by 80--94% ([@B237]), shedding light on the possibility of interventions that can be used to potentially mitigate adverse effects of IMiDs.

Another factor to consider is the multifaceted nature of neuroinflammation. Neuroinflammation sometimes promotes recovery from injury and is necessary at certain time points. For example, 50% of mTBI patients experience meningeal vascular injury from which they recover via actions of inflammatory myeloid cells. Subduing inflammation post-injury may potentially prevent positive effects of inflammation ([@B218]). As the inflammatory response is time-dependent and multi-faceted, IMiDs, which target both TNFR1 and TNFR2 activation, must be administered at timepoints corresponding to the detrimental effects of inflammation when treating various neurological diseases.

After the most efficacious thalidomide analogs are chosen for clinical studies following preclinical research, phase I trials to evaluate their safety and efficacy in humans with neurodegenerative diseases must be designed and conducted. As thalidomide analogs prevent and mitigate inflammation, clinical trials should be focused on AD patients that demonstrate elevated biomarkers associated with increased neuroinflammation.

Testing the efficacy of thalidomide analogs in conjunction with other drugs targeting different aspects of inflammation (i.e., RXR/PPARγ agonists) or neurodegeneration to enhance neuroprotective effects could also be taken into consideration. Furthermore, as enhancing oral bioavailability of the drug has been an issue due to low drug solubility, finding ways to enhance drug solubility while maintaining its oral delivery method is also critical. Delivering lower doses of thalidomide and analogs via solid dispersions is a potential alternative that can increase bioavailability ([@B16]), especially for patients with diminished drug absorption abilities.

Summary {#S9}
=======

Repurposing drugs already on the market and modifying existing pharmacologic structures could yield therapeutic interventions capable of meeting pressing needs for neurological disease. Among drugs already on the market, thalidomide has shown great success despite its controversial history, yielding several analogs that have been approved for the treatment of diseases ranging from multiple myeloma to arthritis. Recent clinical studies of thalidomide have demonstrated that its preclinical promise in animal models of neurodegeneration does not translate to human disease consequent to dose-limiting adverse actions. Translational studies of second, third and fourth generation drugs have yet to be undertaken, and there is recent promising preclinical data on pomalidomide that, if cross-validated, may be supportive of human trials. Small, open label clinical trials of the anti-TNF-α antibody strategy involving perispinal injection suggest that targeting TNF-α is a reasonable approach to potentially treat a range of neurodegenerative disorders. Recent medicinal chemistry studies on the backbone of the classical glutarimide and phthalimide moieties that are common to thalidomide, lenalidomide, and pomalidomide indicate that we can separate pharmacological actions from one another. By altering the chemical structure of thalidomide and its analogs, we may be able to increase potency and bioavailability of IMiDs, and reduce their adverse action, possibly expanding their use to target neuroinflammation to ameliorate symptoms of neurological disease and even slow their progression.

Preclinical studies on TNF-α inhibition using thalidomide and IMiDs in models of diseases such as ALS, PD, AD, and TBI have shown promise, indicating the potential for the advancement of select members of this drug class from the bench to clinical trials and eventually, to the bedside of patients of neurological disease in need of treatment.
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A β

:   Beta-amyloid

Ach

:   acetylcholine

AD

:   Alzheimer's disease

ALS

:   amyotrophic lateral sclerosis

APP

:   amyloid precursor protein

ARE

:   AU-rich element

BBB

:   blood--brain barrier

CCI

:   controlled cortical impact

COX-2

:   cyclooxygenase-2

ChEI

:   cholinesterase inhibitor

CNS

:   central nervous system

CSF

:   cerebrospinal fluid

DA

:   dopaminergic

DAMP

:   damage-associated molecular pattern

HD

:   Huntington's disease

IFN

:   interferon

IL

:   interleukin

IMiD

:   immunomodulatory imide drug

iNOS

:   inducible nitric oxide synthase

LPS

:   lipopolysaccharide

LTD

:   long-term depression

LTP

:   long-term potentiation

MAPK

:   mitogen-activated protein kinases

MS

:   multiple sclerosis

mTBI

:   mild traumatic brain injury

NF- κ B

:   nuclear factor kappa-light-chain-enhancer of activated B cells

PAMP

:   pathogen-associated molecular pattern

PD

:   Parkinson's disease

PNS

:   peripheral nervous system

PPAR γ

:   peroxisome proliferator-activated receptor gamma

pTau

:   phosphorylated tau

ROS

:   reactive oxygen species

TBI

:   traumatic brain injury

TBM

:   tuberculous meningitis

TGF- β

:   transforming growth factor beta

TLRs

:   toll-like receptors

TNF- α

:   tumor necrosis factor alpha

UTR

:   untranslated region
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